Far beyond the usual biomarkers in breast cancer: A review

Journal of Cancer

Volumn 5, Issue 7, 2014, Pages 559-571

  Pultz, Brunna dos Anjos ^a   da Luz, Felipe Andrés Cordero ^a   de Faria, Paulo Rogério ^a   Oliveira, Ana Paula Lima ^a   de Araújo, Rogério Agenor ^b   Silva, Marcelo José Barbosa ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b Setor de Oncologia Hospital de Clínicas de Uberlândia   (Brazil)

Author keywords

Biomarkers; Breast cancer; Chemotherapy resistance; Early diagnosis; Prognosis

Indexed keywords

EID: 84905491265     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8925     Document Type: Review

References (127)

1. Porter P. Westernizing women's risks? Breast cancer in lower-income countries. The New England journal of medicine. 2008; 358: 213-6. doi:10.1056/NEJMp0708307.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63: 11-30. doi:10.3322/caac.21166.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; 55: 74-108.
4. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001; 358: 1340-2. doi:10.1016/S0140-6736(01)06449-2.
5. Dundar PE, Ozmen D, Ozturk B, Haspolat G, Akyildiz F, Coban S, et al. The knowledge and attitudes of breast self-examination and mammography in a group of women in a rural area in western Turkey. BMC cancer. 2006; 6: 43. doi:10.1186/1471-2407-6-43.
6. Pisano ED, Yaffe MJ. Digital mammography. Radiology. 2005; 234: 353-62. doi:10.1148/radiol.2342030897.
7. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24: 2137-50. doi:10.1200/JCO.2005.05.2308.
8. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. British journal of cancer. 1987; 55: 61-6.
9. Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast cancer research and treatment. 1992; 21: 173-80.
10. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25: 5815-24. doi:10.1200/JCO.2007.11.3886.
11. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351: 1451-67.
12. Hrstka R, Brychtova V, Fabian P, Vojtesek B, Svoboda M. AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Disease markers. 2013; 35: 207-12. doi:10.1155/2013/761537.
13. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28: 3239-47. doi:10.1200/JCO.2008.21.6457.
14. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England journal of medicine. 2007; 357: 2666-76. doi:10.1056/NEJMoa072113.
15. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The Journal of pathology. 2005; 205: 275-92. doi:10.1002/path.1706.
16. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clinical chemistry. 2002; 48: 1194-7.
17. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast cancer research and treatment. 1993; 24: 195-208.
18. Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984; 224: 1198-206.
19. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer research. 2001; 61: 4851-7.
20. Deutscher SL, Dickerson M, Gui G, Newton J, Holm JE, Vogeltanz-Holm N, et al. Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC cancer. 2010; 10: 519. doi:10.1186/1471-2407-10-519.
21. Qin W, Gui G, Zhang K, Twelves D, Kliethermes B, Sauter ER. Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC cancer. 2012; 12: 52. doi:10.1186/1471-2407-12-52.
22. Watson MA, Fleming TP. Isolation of differentially expressed sequence tags from human breast cancer. Cancer research. 1994; 54: 4598-602.
23. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer research. 1996; 56: 860-5.
24. Huang Y, Zhang HQ, Wang J, Song XG, Wang GH, Guan Q, et al. Cloning expression, monoclonal antibody preparation and serologic study of mammaglobin in breast cancer. Neoplasma. 2011; 58: 436-40.
25. Galvis-Jimenez JM, Curtidor H, Patarroyo MA, Monterrey P, Ramirez-Clavijo SR. Mammaglobin peptide as a novel biomarker for breast cancer detection. Cancer biology & therapy. 2013; 14: 327-32. doi:10.4161/cbt.23614.
26. Lee GW, Kim JY, Koh EH, Kang D, Choi DS, Maeng KY, et al. Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer. Genetics and molecular research: GMR. 2012; 11: 4034-42. doi:10.4238/2012.November.28.2.
27. Liu Y, Ma L, Liu X, Wang L. Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer. Experimental and therapeutic medicine. 2012; 3: 550-4. doi:10.3892/etm.2011.429.
28. Luo MH, Huang YH, Ni YB, Tsang JY, Chan SK, Shao MM, et al. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Human pathology. 2013; 44: 1241-50. doi:10.1016/j.humpath.2012.10.009.
29. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, et al. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013; 62: 267-74. doi:10.1111/j.1365-2559.2012.04344.x.
30. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004; 22: 691-8. doi:10.1200/JCO.2004.01.072.
31. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979; 16: 885-93.
32. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, et al. Osteopontin expression and distribution in human carcinomas. The American journal of pathology. 1994; 145: 610-23.
33. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncology reports. 2011; 25: 433-41. doi:10.3892/or.2010.1106.
34. Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, et al. Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology letters. 2013; 6: 1559-64. doi:10.3892/ol.2013.1600.
35. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. British journal of cancer. 2010; 103: 861-9. doi:10.1038/sj.bjc.6605834.
36. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011; 32: 477-87. doi:10.1093/carcin/bgr009.
37. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006; 25: 2192-202. doi:10.1038/sj.onc.1209248.
38. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. International journal of cancer Journal international du cancer. 2008; 122: 889-97. doi:10.1002/ijc.23204.
39. Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, et al. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer epidemiology. 2013. doi:10.1016/j.canep.2013.08.005.
40. Ortiz-Martinez F, Perez-Balaguer A, Ciprian D, Andres L, Ponce J, Adrover E, et al. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Human pathology. 2013. doi:10.1016/j.humpath.2013.10.015.
41. Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. Journal of the American College of Surgeons. 2013; 217: 17-26; discussion doi:10.1016/j.jamcollsurg.2013.02.025.
42. Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast cancer research: BCR. 2014; 16: R8. doi:10.1186/bcr3600.
43. Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Endocr Relat Cancer. 2012; 19: R115-29. doi:10.1530/ERC-12-0060.
44. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007; 39: 870-4. doi:10.1038/ng2075.
45. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447: 1087-93. doi:10.1038/nature05887.
46. Kim S, Dubrovska A, Salamone RJ, Walker JR, Grandinetti KB, Bonamy GM, et al. FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. PloS one. 2013; 8: e51671. doi:10.1371/journal.pone.0051671.
47. Zhu X, Asa SL, Ezzat S. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol. 2009; 23: 1397-405. doi:10.1210/me.2009-0071.
48. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res. 2004; 2: 643-52.
49. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15: 356-62. doi:10.1038/ng0497-356.
50. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 2007; 101: 249-57. doi:10.1007/s10549-006-9295-8.
51. Nakajima H, Sakaguchi K, Fujiwara I, Mizuta M, Tsuruga M, Magae J, et al. Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers. Biochem Biophys Res Commun. 2007; 356: 260-5. doi:10.1016/j.bbrc.2007.02.136.
52. Milovanovic Z, Dzodic R, Susnjar S, Plesinac-Karapandzic V, Juranic Z, Tatic S. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen. J BUON. 2011; 16: 46-51.
53. Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF. PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett. 2013; 6: 161-8. doi:10.3892/ol.2013.1331.
54. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. British journal of cancer. 2006; 95: 1056-61. doi:10.1038/sj.bjc.6603384.
55. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends in biochemical sciences. 2010; 35: 669-75. doi:10.1016/j.tibs.2010.07.003.
56. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer cell. 2011; 19: 416-28. doi:10.1016/j.ccr.2011.02.014.
57. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer cell. 2010; 17: 41-52. doi:10.1016/j.ccr.2009.11.023.
58. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29: 4741-51. doi:10.1038/onc.2010.215.
59. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11. doi:10.1038/35102167.
60. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66: 11271-8. doi:10.1158/0008-5472.CAN-06-2044.
61. Castano Z, Fillmore CM, Kim CF, McAllister SS. The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells. Semin Cancer Biol. 2012; 22: 462-70. doi:10.1016/j.semcancer.2012.04.006.
62. Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, et al. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone. Chin Med J (Engl). 2008; 121: 1980-6.
63. Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002; 21: 3241-6. doi:10.1038/sj.onc.1205416.
64. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011; 9: 1644-57. doi:10.1158/1541-7786.MCR-11-0371.
65. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154: 61-74. doi:10.1016/j.cell.2013.06.005.
66. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-717. doi:10.1016/S0140-6736(05)66544-0.
67. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. The Journal of pharmacology and experimental therapeutics. 2004; 310: 1062-75. doi:10.1124/jpet.104.065607.
68. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast cancer research and treatment. 2004; 85: 151-9. doi:10.1023/B:BREA.0000025406.31193.e8.
69. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. Journal of pharmaceutical sciences. 2007; 96: 2224-31. doi:10.1002/jps.20892.
70. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006; 25: 1679-91. doi:10.1038/sj.onc.1209377.
71. Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. British journal of clinical pharmacology. 2011; 71: 737-50. doi:10.1111/j.1365-2125.2011.03905.x.
72. Zafra-Ceres M, de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Duenas EM, et al. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer. International journal of medical sciences. 2013; 10: 932-7. doi:10.7150/ijms.5708.
73. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. Journal of the National Cancer Institute. 2012; 104: 441-51. doi:10.1093/jnci/djs125.
74. German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA, et al. Carcinogenesis of PIK3CA. Hered Cancer Clin Pract. 2013; 11: 5. doi:10.1186/1897-4287-11-5.
75. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199-209. doi:10.1056/NEJMoa1213261.
76. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70. doi:10.1038/nature11412.
77. Fu X, Osborne CK, SchiffR. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast. 2013. doi:10.1016/j.breast.2013.08.001.
78. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sanchez V, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013; 110: 14372-7. doi:10.1073/pnas.1303204110.
79. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. British journal of cancer. 2013; 108: 1807-9. doi:10.1038/bjc.2013.164.
80. Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast cancer research and treatment. 2013; 139: 39-49. doi:10.1007/s10549-013-2529-7.
81. Ciocca DR, Fanelli MA. Estrogen receptors and cell proliferation in breast cancer. Trends in endocrinology and metabolism: TEM. 1997; 8: 313-21.
82. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer research. 1995; 55: 3902-7.
83. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nature reviews Genetics. 2008; 9: 541-53. doi:10.1038/nrg2340.
84. Liu R, Takayama S, Zheng Y, Froesch B, Chen GQ, Zhang X, et al. Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells. The Journal of biological chemistry. 1998; 273: 16985-92.
85. Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009; 137: 1259-71. doi:10.1016/j.cell.2009.04.043.
86. Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nature communications. 2013; 4: 2175. doi:10.1038/ncomms3175.
87. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994; 77: 63-71.
88. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta. 2013; 1835: 46-60. doi:10.1016/j.bbcan.2012.10.002.
89. Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi J, et al. STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res. 2012; 26: 325-35. doi:10.7555/JBR.26.20110050.
90. Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK, Cho CH, et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 2013; 11: 31-42. doi:10.1158/1541-7786.MCR-12-0217.
91. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006; 12: 20-8. doi:10.1158/1078-0432.CCR-04-1749.
92. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003; 9: 594-600.
93. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews Cancer. 2002; 2: 161-74. doi:10.1038/nrc745.
94. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Science signaling. 2008; 1: re6. doi:10.1126/scisignal.127re6.
95. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocrine-related cancer. 2005; 12: 215-27. doi:10.1677/erc.1.00719.
96. Zhu D, Zha X, Hu M, Tao A, Zhou H, Zhou X, et al. High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy. Medical oncology. 2012; 29: 3207-15. doi:10.1007/s12032-012-0239-3.
97. Fu ZY, Lv JH, Ma CY, Yang DP, Wang T. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2011; 65: 163-7. doi:10.1016/j.biopha.2011.02.004.
98. Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H, et al. TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells. Journal of proteome research. 2013; 12: 4136-51. doi:10.1021/pr400457u.
99. Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, et al. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34: 1161-70. doi:10.1007/s13277-013-0659-5.
100. Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role. Cell. 2010; 140: 445-9. doi:10.1016/j.cell.2010.02.007.
101. Malik F, Korkaya H, Clouthier SG, Wicha MS. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell cycle. 2012; 11: 2780-1. doi:10.4161/cc.21395.
102. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nature genetics. 2009; 41: 843-8. doi:10.1038/ng.392.
103. Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y, et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PloS one. 2012; 7: e40008. doi:10.1371/journal.pone.0040008.
104. Wang L, Yuan C, Lv K, Xie S, Fu P, Liu X, et al. Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PloS one. 2013; 8: e67373. doi:10.1371/journal.pone.0067373.
105. Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. International journal of radiation oncology, biology, physics. 2010; 76: 5-8. doi:10.1016/j.ijrobp.2009.08.028.
106. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-54.
107. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
108. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33. doi:10.1016/j.cell.2009.01.002.
109. McDaneld TG. MicroRNA: mechanism of gene regulation and application to livestock. Journal of animal science. 2009; 87: E21-8. doi:10.2527/jas.2008-1303.
110. Manchester FoLSatUo. Homo sapiens miRNAs.
111. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8. doi:10.1038/nature03702.
112. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in molecular medicine. 2011; 17: 313-9. doi:10.1016/j.molmed.2011.01.006.
113. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of surgery. 2010; 251: 499-505. doi:10.1097/SLA.0b013e3181cc939f.
114. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010; 15: 673-82. doi:10.1634/theoncologist.2010-0103.
115. Lv M, Zhu X, Chen W, Zhao J, Tang J. Searching for candidate microRNA biomarkers in detection of breast cancer: a meta-analysis. Cancer biomarkers: section A of Disease markers. 2013; 13: 395-401. doi:10.3233/CBM-130379.
116. Schwarzenbacher D, Balic M, Pichler M. The role of microRNAs in breast cancer stem cells. International journal of molecular sciences. 2013; 14: 14712-23. doi:10.3390/ijms140714712.
117. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of biological chemistry. 2011; 286: 19127-37. doi:10.1074/jbc. M110.216887.
118. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert opinion on therapeutic targets. 2013; 17: 1073-80. doi:10.1517/14728222.2013.819853.
119. McCafferty MP, McNeill RE, Miller N, Kerin MJ. Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. Breast cancer research and treatment. 2009; 116: 425-32. doi:10.1007/s10549-009-0429-7.
120. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic acids research. 2009; 37: 4850-61. doi:10.1093/nar/gkp500.
121. Rouzier R, Pronzato P, Chereau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast cancer research and treatment. 2013; 139: 621-37. doi:10.1007/s10549-013-2559-1.
122. Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer investigation. 2009; 27: 953-9. doi:10.3109/07357900903275217.
123. Bacchi CE, Prisco F, Carvalho FM, Ojopi EB, Saad ED. Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil. Revista da Associacao Medica Brasileira. 2010; 56: 186-91.
124. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2010; 13: 381-7. doi:10.1111/j.1524-4733.2010.00724.x.
125. Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast cancer research and treatment. 2011; 127: 739-49. doi:10.1007/s10549-010-1243-y.
126. Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. The American journal of managed care. 2010; 16: e333-42.
127. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. European journal of cancer. 2010; 46: 1382-91. doi:10.1016/j.ejca.2010.02.035